Studies immune cell changes in psoriasis patients taking tildrakizumab
Looks at immune cells in skin and blood before and after tildrakizumab treatment.
Plain-language title generated from the registry record
Registry title: Psoriatic Immune Response to Tildrakizumab
Key facts
- Where
- San Francisco, United StatesSee the site
- Phase
- Phase 4
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 75 years old?
Source: NCT05390515, who can take part
Where in United States
- University of California San FranciscoSan Francisco, United StatesTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- University of California, San Francisco
- Trial code
- NCT05390515
- Record updated
- 4 June 2026
- Original description
This study aims to assess cutaneous and blood immune cell function of patients with psoriasis before and after initiation of treatment with the IL23 blocker, tildrakizumab.Read full original descriptionShow less
Psoriatic Immune Response to Tildrakizumab
This study aims to assess cutaneous and blood immune cell function of patients with psoriasis before and after initiation of treatment with the IL23 blocker, tildrakizumab.
Inclusion: 18 years of age or older; Patients with moderate-severe psoriasis or > 5% body surface area affected.
Exclusion: tuberculosis or other active serious infection; active systemic malignancy; Presence of a condition or abnormality that in the opinion of the Investigator would compromise the safety of the patient or the quality of the data; taking systemic immunosuppressives in the last 4 weeks; pregnancy; severe immunodeficiency (either from genetic or infectious causes); breast-feeding.